I-124 PET Directed Redifferentiation Therapy for Radioiodine Refractory Thyroid Cancer: the I-FIRST Study

  • Scott, Andrew (Primary Chief Investigator (PCI))
  • Robinson, Bruce (Chief Investigator (CI))
  • Clifton-Bligh, Roderick (Chief Investigator (CI))
  • Barnes, Elizabeth Helen (Chief Investigator (CI))
  • Pattison, David (Chief Investigator (CI))
  • Gilfillan, Christopher (Chief Investigator (CI))
  • Francis, Roslyn J. (Chief Investigator (CI))
  • Bailey, Dale L. (Chief Investigator (CI))
  • Solomon, Benjamin J. (Chief Investigator (CI))
  • Mulhern, Brendan (Chief Investigator (CI))

Project: Research

Project Details

Short titleRedifferentiation therapy for thyroid cancer
AcronymI-First
StatusActive
Effective start/end date1/06/21 → 31/05/26

Funding

  • Medical Research Future Fund (MRFF): A$2,708,660.70

Keywords

  • THYROID CANCER RADIOIODINE REDIFFERENTIATION